Article Per Year (5 Year)
p-Index From 2019 - 2024
0.444
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmacology and Therapy
Woro Rukmi Pratiwi
Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Expression of VEGF-A And COX-2 mRNA in non-steroidal anti-inflammatory drugs treated rat primary colonic fibroblast Andrew Limavanady; Jonathan J; Gloria Evita Thalia; Rasya Mayora; Ade Saputri; Rahmi Ayu Wijayaningsih; Eko Purnomo; Fara Silvia Yuliani; Woro Rukmi Pratiwi; Dwi Aris Agung Nugrahaningsih
Indonesian Journal of Pharmacology and Therapy Vol 1 No 1 (2020)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (253.945 KB) | DOI: 10.22146/ijpther.508

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) is often used to shorten recovery time after surgery, including after colon anastomosis surgery. Studies showed that NSAIDs might involve in the development of colon anastomotic leakage. However, the effect of NSAIDs in colon anastomosis leakage is still a subject of controversy. Studies indicated that selectivity of COX-2 might have a role in the deleterious effect of NSAIDs in colon anastomosis. Disruption of VEGF-A by NSAIDs also suspected to be the culprit in the development of anastomosis leakage during NSAIDs treatment. This study aimed to investigate the NSAIDs effect toward VEGF-A and COX-2 mRNA in rat primary colonic fibroblast. The in vitro study was conducted using fibroblast isolated from rat colon. The isolated fibroblast was divided into 4 groups of treatment i.e.controlgroup, acetaminophen group, metamizole group, and ketorolacgroup. After 48 h of treatment, the cell was harvested and the RNA was isolated. The expression of VEGF-A and COX-2 mRNA was conducted using semi-quantitative PCR(sq-PCR). Both VEGF-A and COX-2 were not expressed in untreated rat colon fibroblast. However, VEGF-A mRNA washighly expressed in the ketorolacgroup. Interestingly, COX-2 mRNA couldbe seen in the ketorolac and metamizole groups but not in the acetaminophen group. The COX-2 mRNA expression wasthe highest in ketorolac treated rat colon fibroblast. It can be concluded that the effect of various kinds of NSAIDs towards VEGF-A and COX-2 mRNA expression of colon fibroblasts is different. This condition is duetotheir different inhibitory selectivity towards COX-1 and COX2.
Drugs repurposing for COVID-19: phase III clinical trial evaluation Woro Rukmi Pratiwi
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (232.093 KB) | DOI: 10.22146/ijpther.1228

Abstract

World Health Organization (WHO) has announced coronavirus disease 2019 (COVID-19) as a global pandemic which is the largest public health crisis in this century. The spread of COVID-19 is still not well-controlled even become global health threat. As new disease, the specific drugs for COVID-19 have not been available, yet. Face of this condition, repurposing existing drugs become the best options in order to meet the urgently need of the effective drugs. In this article, the clinical trial results of some drugs for the treatment of COVID-19 included hydroxychloroquine, chloroquine, lopinavir/ritonavir, remdesivir, oseltamivir, favipiravir, and corticosteroids were reviewed. Hydroxychloroquine, choloquine and lopinavir/ritonavir were shown to be ineffective. Therefore, they were excluded from the list of drugs for the tratment of COVID-19 by WHO and the National Agency of Drug and Food Control of Republic of Indonesia (NCDE NA-DFC RI). Furthermore, NA-DFC RI has issued an emergency use authorization (EUA) for the use of remdesivir and favipiravir for the treatment of COVID-19.
Co-Authors Ade Saputri Andrew Limavanady Eko Purnomo Gloria Evita Thalia Jonathan J Nugrahaningsih, Dwi Aris Agung Rahmi Ayu Wijayaningsih Rasya Mayora Yuliani, Fara Silvia